The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Prostate Carcinoma in the Journal for ImmunoTherapy of Cancer on December 20, 2016SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. The Prostate Carcinoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations on several new agents, including the immunotherapy drug sipuleucel-T, which have been approved or are currently being investigated for the management of advanced prostate cancer.
Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer Consensus statement on immunotherapy for the treatment of prostate carcinoma".
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com